CMS Updates Guidelines for Antipsychotic Medication Screening for TD
The Medicare Physician Fee Schedule has updated its guidelines, urging that all patients prescribed antipsychotic medications undergo screening for tardive dyskinesia (TD). TD is a movement disorder stemming from prolonged use of medications blocking dopamine receptors, found in antipsychotic and antiemetic treatments. This disorder often presents as involuntary, repetitive movements in various body parts.
Kirby P. Williams, MSN, PMHNP-BC, CEO of The PMHNP Source, emphasized early detection's importance, noting TD can lead to significant functional impairments affecting employment, communication, and daily living tasks. In an interview with The Clinical Advisor, Williams stated, “there is also the very real possibility that TD can become permanent.” Although FDA-approved treatments are available, timely detection is key to optimizing patient support and care.
The Centers for Medicare & Medicaid Services (CMS) expanded its policy in January 2026, now advising TD screening for all patients on antipsychotics, broadening its scope from a prior focus primarily on those with diagnosed diabetes. This policy, known as the Antipsychotic-Medication-Associated Physical Health Condition Assessment and Monitoring, reflects its expanded application.
Williams highlighted the Abnormal Involuntary Movement Scale (AIMS) as a validated tool for TD screening. Clinicians must not only administer this scale but also assess the practical impacts of movements on a patient’s daily activities and consider any pre-existing conditions influencing the assessment.
Currently, TD affects over 600,000 individuals in the U.S., yet remains underdiagnosed. A 2025 study indicated only 4.9% of patients with TD-consistent symptoms received a formal diagnosis. Williams suggested that increased screening, encouraged by CMS, might improve diagnosis rates, enhancing healthcare providers’ understanding of TD.
The CMS policy applies to patients under Medicare and clinicians qualifying for the Merit-based Incentive Payment System (MIPS). Williams advocated for comprehensive measures, including education and workflow integration, stressing that the outcome should prioritize patient well-being over procedural compliance.
Once patients are identified with TD, management options include adjusting antipsychotic treatments or considering symptomatic pharmacologic therapies, though guidance is limited. Williams stressed the necessity of nonpharmacologic support for patients not responding adequately to medication or those seeking alternative management strategies, recommending disciplines like occupational therapy to enhance support and promote a holistic approach to TD care.